Committee Members

The Medical Marijuana Act Oversight Committee was established to evaluate and make recommendations regarding the implementation of Title 16, Ch 49A of the Delaware Code. It consists of nine members who possess the qualifications and are appointed as follows:

• One member, appointed by the President Pro Tempore of the Senate.
  • Senator Elizabeth Lockman
• One member, appointed by the Speaker of the House.
  • Representative Stephanie T. Bolden
• The Secretary of the Department, or a designee appointed by the Secretary.
  • Dr. Karyl Rattay — Director, Division of Public Health
• Two medical professionals, each licensed in Delaware, with experience in medical marijuana issues, appointed by the governor.
  • Dr. Jason Silversteen — Neurologist
  • VACANT
• One member with experience in policy development or implementation in the field of medical marijuana, appointed by the governor.
  • Joe Bryant – Office of the Governor
• Three members who each shall be a cardholder, as defined in §4902A of this title, appointed by the governor.
  • Thomas Shabazz – Patient Cardholder
  • VACANT
  • Susan Kelly – Caregiver Cardholder

Committee Directive

The members of the Medical Marijuana Oversight Committee shall serve at the pleasure of the appointing authority. A quorum shall consist of 51 percent of the membership of the Oversight Committee. The Oversight Committee shall select a chair and vice chair from among its members. Staff support for the Oversight Committee shall be provided by DHSS. The Oversight Committee shall meet at least two times per year for the purpose of evaluating and making recommendations to the governor, the general assembly, and DHSS regarding the following:

• The ability of qualifying patients in all areas of the state to obtain timely access to high-quality medical marijuana.
• The effectiveness of the registered compassion centers, individually and together, in serving the needs of qualifying patients, including the provision of educational and support services, the reasonableness of their fees, whether they are generating any complaints or security problems, and the sufficiency of the number operating to serve the registered qualifying patients of Delaware.
• The effectiveness of the registered safety compliance facility or facilities, including whether a sufficient number are operating.
• The sufficiency of the regulatory and security safeguards contained in this chapter and adopted by the department to ensure that access to and use of marijuana cultivated is provided only to cardholders authorized for such purposes.
• Any recommended additions or revisions to the department regulations or this chapter, including relating to security, safe handling, labeling, and nomenclature.
• Any research studies regarding health effects of medical marijuana for patients.